Portola Pharmaceuticals Inc (PTLA) 23.48 $PTLA
Portola's Betrixaban Study Design Published - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Apr 15, 3:30PM CDT
Portola announced the publication of the design and rationale of the phase III APEX study on betrixaban.
Portola Pharmaceuticals Announces Publication of Phase 3 APEX Study Design and Rationale in American Heart Journal
GlobeNewswire - Mon Apr 14, 7:08AM CDT
Portola Pharmaceuticals (Nasdaq
TLA) today announced publication of the design and rationale of the Phase 3 APEX (Acute Medically Ill VTE Prevention with Extended Duration Betrixaban) Study in the March 2014 issue of the American Heart Journal.Betrixaban, the Company's wholly-owned, oral, once-daily Factor Xa anticoagulant, is being evaluated in the only ongoing global, pivotal study of in-hospital and post-discharge prevention of venous thromboembolism (VTE), or blood clots, in patients who have been hospitalized for medical conditions, such as heart failure, stroke, infection and pulmonary disease.
Enrollment in Expansion Phase of Trials, Results and Initiation of Phase 2 Studies and Stock Movements - Analyst Notes on Pfizer, Cytokinetics, Portola Pharmaceuticals, Volcano, and Array BioPharma
PR Newswire - Wed Apr 09, 7:00AM CDT
Today, Analysts Review released its analysts' notes regarding Pfizer Inc. (NYSE: PFE), Cytokinetics, Incorporated (NASDAQ: CYTK), Portola Pharmaceuticals, Inc. (NASDAQ: PTLA), Volcano Corporation (NASDAQ: VOLC), and Array BioPharma, Inc. (NASDAQ: ARRY). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.AnalystsReview.com/register
3 Stocks That Escaped Biotech's March Madness
Todd Campbell, The Motley Fool - Motley Fool - Thu Apr 03, 5:30PM CDT
March was pretty rough for the biotech sector, but there were a few biotech stocks that soared. Among them were Agios Pharmaceuticals , Chimerix, Inc. , and Portola Pharmaceuticals . All three shrugged off the broad biotech sell-off that...
An Interview With Portola Pharmaceuticals CEO Bill Lis
Max Macaluso, The Motley Fool - Motley Fool - Fri Mar 28, 11:22AM CDT
Portola Pharmaceuticals is relatively new to biotech investors and was one of many biotechs to IPO last year. In an effort to better understand the company's pipeline and upcoming catalysts, analyst Max Macaluso recently spoke with the company's...
Portola Pharmaceuticals Initiates Phase 2 Study of Andexanet Alfa, Potential First-in-Class Factor Xa Inhibitor Reversal Agent, and Factor Xa Inhibitor Edoxaban
GlobeNewswire - Thu Mar 27, 7:14AM CDT
Portola Pharmaceuticals (Nasdaq TLA) today announced that it has initiated a Phase 2 proof-of-concept study to evaluate andexanet alfa, the company's investigational Factor Xa inhibitor reversal agent, as a reversal agent for Daiichi Sankyo's oral, once-daily, direct Factor Xa inhibitor edoxaban in healthy volunteers. Portola is developing andexanet alfa, an FDA-designated breakthrough therapy, as a potential first-in-class antidote to reverse the anticoagulation activity of Factor Xa inhibitor-treated patients who are suffering a major bleeding episode or who require emergency surgery. The Company is pursuing an Accelerated Approval pathway for andexanet alfa, which is the only agent that has demonstrated reversal of the anticoagulation activity of Factor Xa inhibitors as measured by biomarkers, including anti-Factor Xa activity, in human studies.
Today’s Top Biotech Stories: Horizon Pharma, Prothena, and Portola Pharmaceuticals
Leo Sun, The Motley Fool - Motley Fool - Wed Mar 19, 8:35AM CDT
Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis. Let's take a look at three stocks -- Horizon Pharma , ...
Portola Pharmaceuticals Initiates Phase 3 Study of Andexanet Alfa, Potential First-in-Class Factor Xa Inhibitor Reversal Agent, Under Accelerated Approval Pathway
GlobeNewswire - Wed Mar 19, 7:15AM CDT
Portola Pharmaceuticals (Nasdaq TLA) today announced that it has initiated a Phase 3 study of andexanet alfa, the company's investigational Factor Xa inhibitor reversal agent. The study will evaluate the safety and efficacy of andexanet alfa with Bristol-Myers Squibb Company (NYSE: BMY) and Pfizer Inc.'s (NYSE: PFE) Factor Xa inhibitor Eliquis(apixaban). Portola is developing andexanet alfa, an FDA-designated breakthrough therapy, as a potential first-in-class antidote to reverse the anticoagulation activity of Factor Xa inhibitor-treated patients who are suffering a major bleeding episode or who require emergency surgery. The Company is pursuing an Accelerated Approval pathway for andexanet alfa, which is the only agent that has demonstrated reversal of the anticoagulation activity of Factor Xa inhibitors as measured by biomarkers, including anti-Factor Xa activity, in human studies.
Portola Pharmaceuticals elects John H. Johnson to board
M2 - Wed Mar 19, 6:42AM CDT
Biopharmaceutical company Portola Pharmaceuticals (NasdaqGS TLA) revealed on Tuesday the addition of John H. Johnson to its board of directors, effective 26 March 2014.
Portola Pharmaceuticals Appoints John H. Johnson to Board of Directors
GlobeNewswire - Tue Mar 18, 7:00AM CDT
Portola Pharmaceuticals (Nasdaq TLA) today announced the appointment of John H. Johnson to its board of directors effective March 26, 2014. Mr. Johnson currently serves as chairman, president and chief executive officer of Dendreon Corporation.
5 Stocks Ready for Breakouts
at The Street - Fri Mar 07, 1:19PM CST
These stocks look poised to break out and trade higher from current levels.
Portola Pharmaceuticals (PTLA) Jumps: Stock Up 8.3% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed Mar 05, 7:51AM CST
Portola Pharmaceuticals, Inc. was a big mover last session, as its shares rose over 8% on the day.
Quarterly and Annual Financial Results Release, Executive Appointments, Upcoming Conferences, and Promotion Announcements - Analyst Notes on NuVasive, IPC, Portola, ICU Medical, and Prothena
PR Newswire - Wed Mar 05, 7:32AM CST
Editor Note: For more information about this release, please scroll to bottom.
Portola Pharmaceuticals Reports Fourth Quarter and Year-End 2013 Financial Results and Provides Corporate Update
GlobeNewswire - Thu Feb 27, 3:14PM CST
Portola Pharmaceuticals (Nasdaq TLA) today announced a corporate update and reported its financial results for the fourth quarter and year ended December 31, 2013.
Portola Pharmaceuticals to Present at the Cowen and Company 34th Annual Health Care Conference
GlobeNewswire - Mon Feb 24, 7:08AM CST
Portola Pharmaceuticals (Nasdaq TLA) today announced that William Lis, chief executive officer, will present at the Cowen and Company 34 Annual Health Care Conference on Monday, March 3, 2014, at 2:10 p.m. Eastern Time in Boston.
Portola Pharmaceuticals to Announce Fourth Quarter and Year End 2013 Financial Results and Host Conference Call on Thursday, February 27, 2014
GlobeNewswire - Thu Feb 20, 7:00AM CST
Portola Pharmaceuticals, Inc. (Nasdaq TLA) today announced that it will host a webcast and conference call to discuss the Company's financial results for the quarter and year ended December 31, 2013, and provide a general business overview on Thursday, February 27, 2014, at 4:30 p.m. Eastern Time (1:30 p.m. Pacific Time).
Nasdaq stocks posting largest percentage decreases
AP - Wed Feb 19, 12:48PM CST
NEW YORK (AP) — A look at the 10 biggest percentage decliners on Nasdaq at 1 p.m.:
Here's Why Big Pharma is Rooting for Portola
Todd Campbell, The Motley Fool - Motley Fool - Wed Feb 05, 8:39AM CST
Big drug makers Pfizer , Bristol-Myers , Johnson & Johnson , and Bayer are always interested in collaborating with emerging biotech companies with promising new therapies. However, their interest in Portola Pharmaceuticals could...
Portola Pharmaceuticals Enters Into Clinical Collaboration Agreement With Bayer and Janssen for Phase 3 Studies of Andexanet Alfa*, Investigational Factor Xa Inhibitor Reversal Agent, and XARELTO(R)
GlobeNewswire - Mon Feb 03, 7:00AM CST
Portola Pharmaceuticals (Nasdaq TLA) today announced that it has entered into a second clinical collaboration agreement with Bayer HealthCare and Janssen Pharmaceuticals, Inc. to evaluate its investigational Factor Xa inhibitor reversal agent, andexanet alfa*, in Phase 3 registration studies with the U.S. Food and Drug Administration (FDA)-approved oral Factor Xa inhibitor XARELTO (rivaroxaban). Portola's original collaboration agreement with Bayer and Janssen, announced in February 2013, covered the conduct of a Phase 2 proof-of-concept study. Interim results of that study were presented in December 2013 at the 55 American Society of Hematology (ASH) Annual Meeting and demonstrated that andexanet alfa can produce an immediate and dose-dependent reversal of the anticoagulation activity of XARELTO. The new clinical collaboration agreement will be in effect through completion of Phase 3 studies with XARELTO and any potential U.S. and EU regulatory approval of andexanet alfa. The Phase 3 studies are expected to start in the first half of 2014.
What You Need to Know About Portola Pharmaceuticals Inc's Anticoagulant Gamechangers
Cory Renauer, The Motley Fool - Motley Fool - Tue Jan 28, 1:14PM CST
In a few years, Portola Pharmaceuticals might be selling a leading thrombosis prophylactic, as well as a much needed antidote for the medication. In an effort to bring its antidote to the market quickly, the company may also benefit Bristol-Myers...
Portola's Betrixaban Study Design Published - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Apr 15, 3:30PM CDT
Portola announced the publication of the design and rationale of the phase III APEX study on betrixaban.
Portola Pharmaceuticals Announces Publication of Phase 3 APEX Study Design and Rationale in American Heart Journal
GlobeNewswire - Mon Apr 14, 7:08AM CDT
Portola Pharmaceuticals (Nasdaq
TLA) today announced publication of the design and rationale of the Phase 3 APEX (Acute Medically Ill VTE Prevention with Extended Duration Betrixaban) Study in the March 2014 issue of the American Heart Journal.Betrixaban, the Company's wholly-owned, oral, once-daily Factor Xa anticoagulant, is being evaluated in the only ongoing global, pivotal study of in-hospital and post-discharge prevention of venous thromboembolism (VTE), or blood clots, in patients who have been hospitalized for medical conditions, such as heart failure, stroke, infection and pulmonary disease. Enrollment in Expansion Phase of Trials, Results and Initiation of Phase 2 Studies and Stock Movements - Analyst Notes on Pfizer, Cytokinetics, Portola Pharmaceuticals, Volcano, and Array BioPharma
PR Newswire - Wed Apr 09, 7:00AM CDT
Today, Analysts Review released its analysts' notes regarding Pfizer Inc. (NYSE: PFE), Cytokinetics, Incorporated (NASDAQ: CYTK), Portola Pharmaceuticals, Inc. (NASDAQ: PTLA), Volcano Corporation (NASDAQ: VOLC), and Array BioPharma, Inc. (NASDAQ: ARRY). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.AnalystsReview.com/register
3 Stocks That Escaped Biotech's March Madness
Todd Campbell, The Motley Fool - Motley Fool - Thu Apr 03, 5:30PM CDT
March was pretty rough for the biotech sector, but there were a few biotech stocks that soared. Among them were Agios Pharmaceuticals , Chimerix, Inc. , and Portola Pharmaceuticals . All three shrugged off the broad biotech sell-off that...
An Interview With Portola Pharmaceuticals CEO Bill Lis
Max Macaluso, The Motley Fool - Motley Fool - Fri Mar 28, 11:22AM CDT
Portola Pharmaceuticals is relatively new to biotech investors and was one of many biotechs to IPO last year. In an effort to better understand the company's pipeline and upcoming catalysts, analyst Max Macaluso recently spoke with the company's...
Portola Pharmaceuticals Initiates Phase 2 Study of Andexanet Alfa, Potential First-in-Class Factor Xa Inhibitor Reversal Agent, and Factor Xa Inhibitor Edoxaban
GlobeNewswire - Thu Mar 27, 7:14AM CDT
Portola Pharmaceuticals (Nasdaq
TLA) today announced that it has initiated a Phase 2 proof-of-concept study to evaluate andexanet alfa, the company's investigational Factor Xa inhibitor reversal agent, as a reversal agent for Daiichi Sankyo's oral, once-daily, direct Factor Xa inhibitor edoxaban in healthy volunteers. Portola is developing andexanet alfa, an FDA-designated breakthrough therapy, as a potential first-in-class antidote to reverse the anticoagulation activity of Factor Xa inhibitor-treated patients who are suffering a major bleeding episode or who require emergency surgery. The Company is pursuing an Accelerated Approval pathway for andexanet alfa, which is the only agent that has demonstrated reversal of the anticoagulation activity of Factor Xa inhibitors as measured by biomarkers, including anti-Factor Xa activity, in human studies. Today’s Top Biotech Stories: Horizon Pharma, Prothena, and Portola Pharmaceuticals
Leo Sun, The Motley Fool - Motley Fool - Wed Mar 19, 8:35AM CDT
Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis. Let's take a look at three stocks -- Horizon Pharma , ...
Portola Pharmaceuticals Initiates Phase 3 Study of Andexanet Alfa, Potential First-in-Class Factor Xa Inhibitor Reversal Agent, Under Accelerated Approval Pathway
GlobeNewswire - Wed Mar 19, 7:15AM CDT
Portola Pharmaceuticals (Nasdaq
TLA) today announced that it has initiated a Phase 3 study of andexanet alfa, the company's investigational Factor Xa inhibitor reversal agent. The study will evaluate the safety and efficacy of andexanet alfa with Bristol-Myers Squibb Company (NYSE: BMY) and Pfizer Inc.'s (NYSE: PFE) Factor Xa inhibitor Eliquis(apixaban). Portola is developing andexanet alfa, an FDA-designated breakthrough therapy, as a potential first-in-class antidote to reverse the anticoagulation activity of Factor Xa inhibitor-treated patients who are suffering a major bleeding episode or who require emergency surgery. The Company is pursuing an Accelerated Approval pathway for andexanet alfa, which is the only agent that has demonstrated reversal of the anticoagulation activity of Factor Xa inhibitors as measured by biomarkers, including anti-Factor Xa activity, in human studies. Portola Pharmaceuticals elects John H. Johnson to board
M2 - Wed Mar 19, 6:42AM CDT
Biopharmaceutical company Portola Pharmaceuticals (NasdaqGS
TLA) revealed on Tuesday the addition of John H. Johnson to its board of directors, effective 26 March 2014. Portola Pharmaceuticals Appoints John H. Johnson to Board of Directors
GlobeNewswire - Tue Mar 18, 7:00AM CDT
Portola Pharmaceuticals (Nasdaq
TLA) today announced the appointment of John H. Johnson to its board of directors effective March 26, 2014. Mr. Johnson currently serves as chairman, president and chief executive officer of Dendreon Corporation. 5 Stocks Ready for Breakouts
at The Street - Fri Mar 07, 1:19PM CST
These stocks look poised to break out and trade higher from current levels.
Portola Pharmaceuticals (PTLA) Jumps: Stock Up 8.3% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed Mar 05, 7:51AM CST
Portola Pharmaceuticals, Inc. was a big mover last session, as its shares rose over 8% on the day.
Quarterly and Annual Financial Results Release, Executive Appointments, Upcoming Conferences, and Promotion Announcements - Analyst Notes on NuVasive, IPC, Portola, ICU Medical, and Prothena
PR Newswire - Wed Mar 05, 7:32AM CST
Editor Note: For more information about this release, please scroll to bottom.
Portola Pharmaceuticals Reports Fourth Quarter and Year-End 2013 Financial Results and Provides Corporate Update
GlobeNewswire - Thu Feb 27, 3:14PM CST
Portola Pharmaceuticals (Nasdaq
TLA) today announced a corporate update and reported its financial results for the fourth quarter and year ended December 31, 2013. Portola Pharmaceuticals to Present at the Cowen and Company 34th Annual Health Care Conference
GlobeNewswire - Mon Feb 24, 7:08AM CST
Portola Pharmaceuticals (Nasdaq
TLA) today announced that William Lis, chief executive officer, will present at the Cowen and Company 34 Annual Health Care Conference on Monday, March 3, 2014, at 2:10 p.m. Eastern Time in Boston. Portola Pharmaceuticals to Announce Fourth Quarter and Year End 2013 Financial Results and Host Conference Call on Thursday, February 27, 2014
GlobeNewswire - Thu Feb 20, 7:00AM CST
Portola Pharmaceuticals, Inc. (Nasdaq
TLA) today announced that it will host a webcast and conference call to discuss the Company's financial results for the quarter and year ended December 31, 2013, and provide a general business overview on Thursday, February 27, 2014, at 4:30 p.m. Eastern Time (1:30 p.m. Pacific Time). Nasdaq stocks posting largest percentage decreases
AP - Wed Feb 19, 12:48PM CST
NEW YORK (AP) — A look at the 10 biggest percentage decliners on Nasdaq at 1 p.m.:
Here's Why Big Pharma is Rooting for Portola
Todd Campbell, The Motley Fool - Motley Fool - Wed Feb 05, 8:39AM CST
Big drug makers Pfizer , Bristol-Myers , Johnson & Johnson , and Bayer are always interested in collaborating with emerging biotech companies with promising new therapies. However, their interest in Portola Pharmaceuticals could...
Portola Pharmaceuticals Enters Into Clinical Collaboration Agreement With Bayer and Janssen for Phase 3 Studies of Andexanet Alfa*, Investigational Factor Xa Inhibitor Reversal Agent, and XARELTO(R)
GlobeNewswire - Mon Feb 03, 7:00AM CST
Portola Pharmaceuticals (Nasdaq
TLA) today announced that it has entered into a second clinical collaboration agreement with Bayer HealthCare and Janssen Pharmaceuticals, Inc. to evaluate its investigational Factor Xa inhibitor reversal agent, andexanet alfa*, in Phase 3 registration studies with the U.S. Food and Drug Administration (FDA)-approved oral Factor Xa inhibitor XARELTO (rivaroxaban). Portola's original collaboration agreement with Bayer and Janssen, announced in February 2013, covered the conduct of a Phase 2 proof-of-concept study. Interim results of that study were presented in December 2013 at the 55 American Society of Hematology (ASH) Annual Meeting and demonstrated that andexanet alfa can produce an immediate and dose-dependent reversal of the anticoagulation activity of XARELTO. The new clinical collaboration agreement will be in effect through completion of Phase 3 studies with XARELTO and any potential U.S. and EU regulatory approval of andexanet alfa. The Phase 3 studies are expected to start in the first half of 2014. What You Need to Know About Portola Pharmaceuticals Inc's Anticoagulant Gamechangers
Cory Renauer, The Motley Fool - Motley Fool - Tue Jan 28, 1:14PM CST
In a few years, Portola Pharmaceuticals might be selling a leading thrombosis prophylactic, as well as a much needed antidote for the medication. In an effort to bring its antidote to the market quickly, the company may also benefit Bristol-Myers...
